Ignite Creation Date:
2025-12-25 @ 3:03 AM
Ignite Modification Date:
2026-05-17 @ 12:21 PM
Study NCT ID:
NCT00449033
Status:
COMPLETED
Last Update Posted:
2015-04-23
First Post:
2007-03-16
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)
Sponsor:
Bayer
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
12006
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None